Equities
  • Price (USD)284.52
  • Today's Change2.14 / 0.76%
  • Shares traded764.02k
  • 1 Year change-10.34%
  • Beta1.6615
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.

  • Revenue in USD (TTM)3.92bn
  • Net income in USD462.28m
  • Incorporated1997
  • Employees21.61k
  • Location
    Align Technology Inc410 North Scottsdale Road, Suite 1300TEMPE 85288United StatesUSA
  • Phone+1 (408) 470-1000
  • Fax+1 (408) 470-1010
  • Websitehttps://www.aligntech.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ALGN:NSQ since
announced
Transaction
value
Cubicure GmbHDeal completed06 Sep 202306 Sep 2023Deal completed-22.82%84.69m
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Insulet Corp1.70bn206.30m12.04bn3.00k61.0116.4043.147.092.822.8222.7810.480.70141.436.00565,700.008.532.7110.263.1468.3565.8112.164.282.6240.740.6590.0030.0224.664,384.78128.77-7.63--
Shockwave Medical Inc730.23m147.28m12.38bn1.47k85.5718.2778.5716.963.863.8619.1318.080.661.047.86497,431.9013.3110.2914.4011.3986.9484.6920.1715.1410.7319.700.52260.0049.11126.45-31.81--72.88--
Cooper Companies Inc3.67bn290.80m17.70bn15.00k90.002.3026.594.830.98960.98967.3638.730.31081.775.95244,420.002.4710.062.6811.3466.0965.547.9329.001.084.920.26490.34698.617.24-23.74-3.6615.1831.95
Hologic Inc3.97bn515.10m17.79bn6.99k36.023.8221.154.482.102.1016.1319.840.4472.705.90567,854.105.8011.406.4813.3855.4460.2912.9820.953.18--0.35650.00-17.124.61-64.98--7.30--
Steris PLC5.41bn566.84m20.21bn17.00k36.073.1517.713.745.675.6754.1864.930.48643.946.05318,081.405.113.995.544.3743.6043.4110.507.901.496.420.339949.058.1313.61-56.12-17.0216.958.74
Baxter International Inc14.81bn-76.00m20.56bn60.00k--2.4417.221.39-0.15085.2229.2316.550.52383.435.48246,883.30-0.2440.1942-0.30540.233335.8938.20-0.46580.36741.043.280.61971,398.942.125.9497.15--0.9829.71
Align Technology, Inc.3.92bn462.28m21.25bn21.61k46.525.6545.815.436.076.0751.4449.960.64973.964.27181,237.607.6716.3411.5124.1470.0671.7211.8023.161.09----0.003.4214.4523.092.15-4.46--
Zimmer Biomet Holdings Inc7.39bn1.02bn24.71bn18.00k24.601.9812.503.344.894.8935.2660.700.34750.91955.24410,794.404.822.215.492.5271.8271.2513.867.280.77847.320.31638.906.55-1.40252.86--9.440.00
West Pharmaceutical Services Inc.2.93bn568.70m26.17bn10.60k47.139.7437.728.947.587.5839.0936.720.79954.205.65276,283.0015.0815.6117.9918.6537.1538.0618.8618.471.95--0.071410.692.1811.432.2823.7628.166.20
Resmed Inc4.58bn958.38m31.48bn10.14k32.946.7927.656.876.506.5031.0731.520.67772.205.99452,086.7014.1713.5915.9815.8955.7856.9820.9119.221.9725.880.178636.6618.0212.5315.1514.6313.404.68
Data as of May 01 2024. Currency figures normalised to Align Technology Inc's reporting currency: US Dollar USD

Institutional shareholders

34.77%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 20238.04m10.70%
BlackRock Fund Advisorsas of 31 Dec 20233.99m5.31%
SSgA Funds Management, Inc.as of 31 Dec 20233.06m4.08%
JPMorgan Investment Management, Inc.as of 31 Dec 20231.89m2.51%
Wellington Management Co. LLPas of 31 Dec 20231.80m2.40%
Geode Capital Management LLCas of 31 Dec 20231.67m2.23%
BlackRock Advisors LLCas of 31 Dec 20231.51m2.01%
AllianceBernstein LPas of 31 Dec 20231.46m1.95%
Sands Capital Management LLCas of 31 Dec 20231.43m1.90%
Polen Capital Management LLCas of 31 Dec 20231.27m1.69%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.